Trial Profile
Post-marketing clinical study of OIF in chronic myeloid leukemia (CML)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 14 Jun 2016 New trial record